Literature DB >> 20639624

Bisphosphonates induce apoptosis of circulating endothelial cells in multiple myeloma patients and in subjects with bisphosphonate-induced osteonecrosis of the jaws.

Alessandro Allegra1, Andrea Alonci, Giuseppa Penna, Angela Granata, Enrico Nastro Siniscalchi, Giacomo Oteri, Saverio Loddo, Diana Teti, Domenico Cicciù, Francesco Saverio De Ponte, Caterina Musolino.   

Abstract

Bisphosphonates (BPs) are the current standard of care for bone lesions in patients with multiple myeloma (MM) but they are associated with a number of side effects such as osteonecrosis of the jaw. The exact mechanisms of osteonecrosis are not elucidated, and its physiopathology is based on several hypotheses such as a decrease in bone remodeling or an inhibitory effect on angiogenesis. The aim of our study was to investigate the mechanism involved in the pathogenesis of osteonecrosis. We examined the apoptosis of circulating endothelial progenitor cells in MM subjects before and after BP treatment and in osteonecrosis patients using a flow-cytometric analysis. Our data showed an increase in endothelial cell apoptosis in MM patients after BP administration and in osteonecrosis subjects. Our study seems in agreement with the hypothesis that BPs can inhibit angiogenesis interfering with endothelial cell proliferation and survival, leading to loss of blood vessels and avascular necrosis.
Copyright © 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20639624     DOI: 10.1159/000313787

Source DB:  PubMed          Journal:  Acta Haematol        ISSN: 0001-5792            Impact factor:   2.195


  15 in total

1.  Bisphosphonates hinder osteoblastic/osteoclastic differentiation in the maxillary sinus mucosa-derived stem cells.

Authors:  Jun Zhang; Jaesuh Park; Jung-Woo Lee; Yong-Dae Kwon; Eun-Cheol Kim
Journal:  Clin Oral Investig       Date:  2017-11-30       Impact factor: 3.573

2.  Osteonecrosis of the jaw associated with everolimus: A case report.

Authors:  Daigo Yamamoto; Yu Tsubota; Toshiki Utsunomiya; Noriko Sueoka; Aiko Ueda; Kayoko Endo; Katsuhiro Yoshikawa; Masanori Kon
Journal:  Mol Clin Oncol       Date:  2016-12-05

Review 3.  Diabetes as a risk factor for medication-related osteonecrosis of the jaw.

Authors:  A Peer; M Khamaisi
Journal:  J Dent Res       Date:  2014-12-04       Impact factor: 6.116

4.  Inhibition of bone loss with surface-modulated, drug-loaded nanoparticles in an intraosseous model of prostate cancer.

Authors:  Isaac M Adjei; Blanka Sharma; Chiranjeevi Peetla; Vinod Labhasetwar
Journal:  J Control Release       Date:  2016-04-15       Impact factor: 9.776

5.  Bone mineralization and vascularization in bisphosphonate-related osteonecrosis of the jaw: an experimental study in the rat.

Authors:  Jean-Daniel Kün-Darbois; Hélène Libouban; Guillaume Mabilleau; Florence Pascaretti-Grizon; Daniel Chappard
Journal:  Clin Oral Investig       Date:  2018-02-16       Impact factor: 3.573

6.  Synergistic combination treatment to break cross talk between cancer cells and bone cells to inhibit progression of bone metastasis.

Authors:  Sivakumar Vijayaraghavalu; Yue Gao; Mohammed Tanjimur Rahman; Richard Rozic; Nima Sharifi; Ronald J Midura; Vinod Labhasetwar
Journal:  Biomaterials       Date:  2019-10-18       Impact factor: 12.479

7.  The effect of bisphosphonates on the endothelial differentiation of mesenchymal stem cells.

Authors:  Dileep Sharma; Stephen Mark Hamlet; Eugen Bogdan Petcu; Saso Ivanovski
Journal:  Sci Rep       Date:  2016-02-09       Impact factor: 4.379

Review 8.  Role of Teriparatide in Medication-Related Osteonecrosis of the Jaws (MRONJ).

Authors:  Yong-Dae Kwon; Deog-Yoon Kim
Journal:  Dent J (Basel)       Date:  2016-11-09

9.  Altered Long Noncoding RNA Expression Profile in Multiple Myeloma Patients with Bisphosphonate-Induced Osteonecrosis of the Jaw.

Authors:  Alessandro Allegra; Manuela Mania; Angela D'Ascola; Giacomo Oteri; Enrico Nastro Siniscalchi; Angela Avenoso; Vanessa Innao; Michele Scuruchi; Andrea Gaetano Allegra; Caterina Musolino; Salvatore Campo
Journal:  Biomed Res Int       Date:  2020-07-02       Impact factor: 3.411

10.  Bone vascularization in normal and disease conditions.

Authors:  Christian Carulli; Massimo Innocenti; Maria Luisa Brandi
Journal:  Front Endocrinol (Lausanne)       Date:  2013-08-26       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.